Maplight Therapeutics, Inc. insider trading

Every open-market purchase and sale by Maplight Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $175M 11 trades by 5 insiders 3 months later: median +14.3% (+12.8% vs S&P 500) Insider sales, 5 years $30.2M 73 trades by 8 insiders 3 months later: median −55.5% (−60.7% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Maplight Therapeutics, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Maplight Therapeutics, Inc.’s insiders pay?

From January 30, 2026 to October 16, 2026, 12 insiders reported 5 open-market purchases and 21 sales not made under a pre-set plan in Maplight Therapeutics, Inc. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 13, 2026 into $3,937 by November 2, 2026, −72.9% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $11,183 (+16.9% a year), and held throughout $11,183 (+16.9%).

Copying Maplight Therapeutics, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Maplight Therapeutics, Inc.'s insiders from February 13, 2026, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

Maplight Therapeutics, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Malenka Robert C.	Director	0	—	—	5	—	February 24, 2026
Hanson Kristopher	General Counsel	0	—	—	3	—	October 16, 2026
Kroeger Christopher A.	Chief Executive Officer	0	—	—	3	—	October 16, 2026
Lillie James Woodruff	Chief Scientific Officer	0	—	—	3	—	October 16, 2026
Catalyst4, Inc.	10% owner	2	—	—	0	—	August 18, 2026
Foff Erin Pennock	Chief Medical Officer	0	—	—	2	—	October 16, 2026
Gillis Jonathan	CAO and Interim CFO	0	—	—	2	—	October 16, 2026
Kreitzer Anatol	Chief Discovery Officer	0	—	—	2	—	October 16, 2026
Cox Troy	Director	1	—	—	0	—	July 28, 2026
Garnett Timothy John	Director	1	—	—	0	—	February 12, 2026
Pavlov George	Director	1	—	—	0	—	February 20, 2026
Setia Vishwas	Chief Financial Officer	0	—	—	1	—	April 17, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Maplight Therapeutics, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Maplight Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −39.8% against the index. After 1 selling crowd, −83.4%. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
April 30, 2026	8 selling	−63.4%	−83.4%	not yet
February 27, 2026	2 buying	+59.1%	−39.8%	not yet

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Maplight Therapeutics, Inc. · Funds · Politicians